M&A - BIOREGENX, INC.

Form Type: 10-Q

Filing Date: 2025-05-15

Corporate Action: Merger

Type: Update

Accession Number: 000168316825003694

Filing Summary: For the first quarter ended March 31, 2025, BioRegenx, Inc. reported total assets of $482,623 and total liabilities amounting to $4,041,547, resulting in a stockholders' deficit of $3,558,924. The company generated revenues of $515,147 with a net loss of $266,854 for this period. Significant expenses included selling, general, and administrative costs totaling $590,368. The financial statements reflect adjustments necessary for fair presentation. The company is undergoing changes after a merger with Findit, Inc., where existing shareholders of BioRegenx received shares in the surviving entity. The merger enhanced their share structure and resulted in a change in control, with the company now continued as BioRegenx, Inc. This merger is reported in compliance with US GAAP. The company has, however, consistently operated at a cash flow deficit, raising concerns about its ability to continue as a going concern without additional funding or operational reforms.

Form Type: 10-K/A

Filing Date: 2025-04-16

Corporate Action: Merger

Type: Update

Accession Number: 000168316825002623

Filing Summary: BioRegenx, Inc. (formerly Findit, Inc.) underwent a merger effective March 8, 2024, where BioRegenx was merged into Findit, resulting in a change of control. This merger involved an exchange of all issued and outstanding common and preferred shares of BioRegenx for 851,977,296 common shares and 3,800 Series A preferred shares of the merged entity, representing 90.0% of the voting securities. Subsequently, holders of Series A and B preferred shares retired their shares, contributing to a loss of 98.47% of voting control. The company aims to implement a reverse stock split to enhance investor appeal. The document also highlights the acquisition of DocSun Biomedical Holdings, Inc. and technology innovations aimed at health diagnostics through artificial intelligence. Additionally, it includes financial metrics and consolidated statements necessary for shareholders and regulatory compliance.

Form Type: 10-K

Filing Date: 2025-04-15

Corporate Action: Merger

Type: Update

Accession Number: 000168316825002614

Filing Summary: BioRegenx, Inc. (formerly Findit, Inc.) underwent a significant merger on March 8, 2024, merging into Findit, Inc. This change resulted in a new company structure where BioRegenx common and preferred shares were exchanged for substantial common shares and a series of preferred shares of the company, representing a significant transfer of control. The merger aimed at improving institutional investor interest and transitioning to a senior exchange. The company's strategy includes a reverse stock split to attract investments and enhance trading capabilities. Furthermore, BioRegenx acquired DocSun Biomedical Holdings, Inc. on January 11, 2024, integrating its advanced artificial intelligence technology into health monitoring initiatives. The company also highlighted collaborative agreements for technology licenses and partnerships, projecting growth in health and wellness sectors moving forward. This annual report provides an overarching view of the company’s financial condition, details on market activities, and insights into future projections and operational strategies.